Why the study?
Improved life expectancy in patients with cancer-associated thrombosis has made it a chronic disease, raising new clinical issues regarding anticoagulation personalization, extended treatment, and bleeding risks.
The review emphasizes the need for personalized anticoagulation and highlights emerging therapies like anti-XI agents for managing cancer-associated thrombosis.
May warrant considering patient/cancer factors for anticoagulation in cancer thrombosis; leaves open optimal personalization strategies.
PURPOSE OF REVIEW: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications. RECENT FINDINGS: Consequently, news issues emerge for clinical practice: anticoagulation therapy personalization is required to optimize the benefit ratio, involving patient characteristics and cancer characteristics. During follow-up, prediction score are designed and investigated to help identify and discriminate patients at risk of venous thromboembolism recurrences and major bleedings. Considering the improved prognosis of patients with cancer and cancer-associated thrombosis, the question of extended treatment arises, representing a major unmet need to date. Finally, new strategies, in particular anti-XI agents that appear attractive options, are currently being evaluated in the treatment of thrombosis associated with cancer. SUMMARY: The improved prognosis of patients with cancer-associated thrombosis is accompanied by new therapeutic strategies to improve the benefit-risk ratio of anticoagulant treatment in these fragile patients, at risk of both venous thromboembolic recurrence and haemorrhagic complication.
No takes yet. Share an insight, caveat, or question.
Mahé et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: